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In the last 20 years, following the identi-
fication of the BRCA1 and BRCA2 genes 
(hereinafter referred to as the BRCA 
genes), preventive pathways have been 
developed for the identification and clini-
cal management of individuals at high risk 
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of developing breast and ovarian cancer due to 
the presence of a pathogenic variant in either 
of these genes. These pathways are aimed at 
educating high-risk subjects on programs tar-
geted toward early diagnosis and cancer risk 
reduction.
The approval of a novel class of drugs, the 
PARP enzyme inhibitors, for the treatment 
of ovarian cancer patients carrying high-risk 
BRCA pathogenic variants has changed this sce-
nario. BRCA testing, in addition to providing 
information on the risk of disease, has become 
also a predictive marker of drug response in 
ovarian carcinoma patients. These recommen-
dations prepared by Associazione Italiana di 
Oncologia Medica (AIOM), Società Italiana 
Genetica Umana (SIGU), Società Italiana 
di Biochimica Clinica e Biologia Molecolare 
Clinica (SIBIOC) and Società Italiana di 
Anatomia Patologica e Citologia Diagnostica – 
Italian Division of the International Academy 
of Pathology (SIAPEC-IAP) are focused on the 
implementation of BRCA testing in the care and 
treatment pathways of ovarian cancer patients.
BRCA testing for the prediction of 
treatment efficacy
Recent population studies have highlighted 
that the prevalence of constitutional BRCA 
pathogenic variants in ovarian cancer patients is 
>10%, independently of age of diagnosis and of 
family history of breast/ovarian cancer [1,2]. The 
prevalence of pathogenic variants progressively 
increases in patients with serous ovarian carci-
noma (17–20%), high-grade serous carcinoma 
(23–25%) and in platinum-sensitive patients 
(30–40%) [3–6]. Furthermore, approximately 
25% of women carrying pathogenic BRCA vari-
ants have a diagnosis of ovarian carcinoma over 
60 years of age [1–3].
Retrospective studies suggest that heterozy-
gosity for a BRCA hereditary pathogenic vari-
ant in ovarian cancer patients is associated with 
a significantly more favorable prognosis and is 
predictive of sensitivity to combination therapies 
containing platinum derivatives [3,7].
Somatic mutations of the BRCA genes have 
been identified in approximately 6% of serous 
ovarian carcinomas [4,6], thus suggesting that 
inactivation of these genes can also occur  during 
cancer progression.
Importantly, it has been shown that BRCA 
gene mutations, whether constitutional or 
somatic, are a biomarker of sensitivity to 
treatment with PARP inhibitors, a class of 
pharmacological agents involved in the repair 
of single-strand DNA breaks, in patients with 
advanced ovarian cancer [8,9]. The therapeutic 
effect of PARP inhibitors in ovarian cancer is 
due to ‘synthetic lethality’, which occurs in cells 
with an inactive double-strand DNA repair 
mechanism mediated by homologous recom-
bination (HR). The BRCA1/2 proteins play 
an essential role in HR [8–13], and their loss of 
function due to constitutional or somatic BRCA 
gene mutations can be one of the major causes 
of HR dysfunction [6,14–15]. Following clinical 
trials, the PARP inhibitor olaparib has been 
registered in October 2014 by EMA as a main-
tenance therapy in patients with relapsed high-
grade serous platinum-sensitive ovarian cancer, 
Fallopian tube cancer and primary peritoneal 
cancer [5,9,16].
Hence, BRCA testing is now a prerequisite 
for the indication of PARP inhibitor therapy. 
However, it is advisable to consider offering the 
test at the time of initial diagnosis to all patients 
with nonmucinous and nonborderline ovarian 
epithelial carcinoma, fallopian tube carcinoma 
and primary peritoneal carcinoma. This approach 
would allow us to obtain early the information on 
the potential sensitivity to PARP inhibitors and 
at the same time it would also pave the way for 
cancer genetic counseling and prevention. The 
timing of BRCA testing should be chosen with 
the patient in order to respect her needs for the 
decision-making process. In addition, the patient 
must be provided with appropriate and thorough 
information regarding all issues associated with a 
positive test outcome.
Types of BRCA testing
The BRCA test on peripheral blood detects con-
stitutional/hereditary variants – that is, those 
which can be transmitted to the offspring (50% 
probability for each child). On the other hand, 
the test conducted on tumor tissue can also iden-
tify the variants acquired by somatic mutations 
during tumor development and progression, in 
addition to constitutional defects. This implies 
that when a variant is identified in tumor DNA, 
its origin (constitutional or somatic) must be 
established by analyzing normal tissue (blood 
or other tissue).
According to available data, 2/3 of the path-
ogenic BRCA variants identified in patients 
affected by ovarian cancer are constitutional 
(present in every cell of the individual) and 
“The timing of BRCA 
testing should be chosen 
with the patient in order to 
respect her needs for the 
decision-making process.”
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1/3 somatic (confined to tumor tissue) [4,6]. 
Constitutional BRCA variants are nearly always 
inherited from one parent; less than 1% of cases 
are due to de novo mutations, occurring in the 
parental germ cells or in utero.
In the clinical setting, mutation screen-
ing of BRCA1 and BRCA2 is usually carried 
out by sequencing of all coding exons (n = 22 
and n = 26, respectively) and corresponding 
exon/intron junctions. This allows detection 
of point variations (single nucleotide substitu-
tions and insertions/deletions of one or a few 
bases) in the DNA sequence. These alterations 
encompass more than 90% of BRCA pathogenic 
variants occurring in the coding regions of both 
genes. In order to maximize sensitivity, the test 
must include the search for large genomic rear-
rangements (i.e., deletions or duplications of 
one or more exons, or of the whole gene), which 
account for a variable proportion of constitu-
tional BRCA variants across populations, usu-
ally not exceeding 10%. These types of changes 
can be investigated by multiplex ligation probe 
dependent amplification or multiplex amplicon 
quantification [17,18].
Currently, sequencing analyses for the detec-
tion of constitutional pathogenic BRCA gene 
variants on peripheral blood is performed in 
most laboratories using different methods. These 
include well-established techniques, namely 
Sanger sequencing, as well as novel technolo-
gies – that is, next-generation sequencing, which 
are under validation [19–24].
There are as yet no standardized tests for 
BRCA analysis in tumor samples. BRCA test-
ing in tumor tissue is more complex than other 
molecular somatic tests already included in rou-
tine cancer diagnosis. This is due to the high 
degree of heterogeneity of potentially patho-
genic variants, which can be observed along 
the entire sequence of BRCA1 and BRCA2 
genes. Furthermore, in addition to the already 
mentioned different types of DNA variations 
(point variations, large deletions/duplications), 
epigenetic alterations (methylation of the regu-
latory regions) can also occur [4,15]. This makes 
it difficult to assess the predictive value, in 
terms of response to treatment, of the different 
BRCA variants, in particular those identified at 
somatic level. Indeed, the available classifica-
tion algorithms have been devised to identify 
constitutional variants associated with a high 
risk of developing breast and ovarian cancer 
(see below). While BRCA mutation test in 
blood DNA is routinely applied in the search of 
constitutional pathogenic variants, the actual 
feasibility of the somatic test by the diagnostic 
laboratory should be verified in advance, in con-
sideration of the inherent methodological diffi-
culties. Laboratories should carry out technical 
assessment procedures and take part in external 
quality control programs of the tests they offer 
(constitutional and/or somatic) [25].
Interpretation of BRCA genetic variants
The mutation spectrum of the BRCA genes is 
very broad, and the interpretation of the clinical 
significance of identified variants is not always 
straightforward. Indeed, variant classification is 
an important aspect of the BRCA testing pro-
cess, particularly when considering that quite 
often clinical testing detects genetic alterations 
not reported in the scientific literature [26]. 
Therefore, although no consolidated stand-
ards exist for the classification of constitutional 
BRCA variants, it is important that laborato-
ries use updated classification criteria, and that 
reports be written up in accordance with good 
laboratory practice recommendations.
The Evidence-based Network for the 
Interpretation of Germline Mutant Alleles 
(ENIGMA) has recently developed specific cri-
teria for interpreting the clinical significance, 
in relation to cancer risk, of constitutional vari-
ants of BRCA genes. These are available on the 
consortium website [27]. However, it must be 
considered that studies in mouse models have 
highlighted that not all BRCA gene variants 
associated with high risk of developing can-
cer are predictors of response to anti-PARP 
therapy [8].
It is therefore necessary that laboratory report-
ing protocols, including the interpretation pro-
cess, be made publicly available. In addition, the 
clinical significance of the BRCA gene variants 
identified should be clearly stated, along with 
a list of the essential information used for the 
classification [26,28]. In this regard, laboratories, 
in addition to taking part in external quality 
control programs, should contribute to a sys-
tematic and centralized collection of all BRCA 
variants observed with the aim to improve their 
classification [25].
BRCA testing in the care & treatment 
pathway
The use of BRCA testing as a treatment decision 
tool implies that it should be readily accessible 
“The use of BRCA testing as 
a treatment decision tool 
implies that it should be 
readily accessible to all 
those patients who may 
benefit from it and that the 
test results be made 
available within a time 
compatible with the 
clinical needs.”
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to all those patients who may benefit from it and 
that the test results be made available within a 
time compatible with the clinical needs.
The models of cancer genetic counseling 
developed in the preventive setting are currently 
insufficient to meet the increasing number of 
BRCA test requests, particularly when the test 
for genetic predisposition also has a predictive 
value for treatment which needs to be deter-
mined in a short time. The optimal model of 
genetic counseling within the prevention path-
way involves detailed information and discus-
sion of the genetic aspects right from the pretest 
stage. On the other hand, the need to obtain test 
results in a timely manner in order to implement 
treatment planning implies that also oncologists 
and gynecologists experienced in oncology can 
directly request the BRCA test to the laboratory. 
Even when the test is performed in the cancer 
treatment setting, the arrangement of full care 
pathways is mandatory, to ensure the correct 
interpretation of the results for clinical purposes, 
the correct way to manage family members at 
risk if a hereditary pathogenic variant is identi-
fied and the correct genetic assessment of cases 
with a noninformative BRCA test result [25–26,28].
Physicians who request the BRCA test must 
receive appropriate updated training in genetic 
oncology. Since prescribers bear final responsibil-
ity for the use of the test result, they must verify 
that the laboratory uses appropriate protocols 
for correct clinical interpretation. Furthermore, 
protocols must be defined for the referral of 
patients with inherited pathogenic variant to 
a clinical cancer genetics team so that family 
members can receive appropriate care, as well as 
for particular cases warranting further genetic 
investigation [28].
Each center must provide clear indications of 
the management pathways to the patients and 
their relatives, outlining the duties and respon-
sibilities of the oncology team, of the laboratory 
and of the clinical cancer genetics team across 
the different phases of the defined care pathway. 
Should recognized standards not be available, 
one should consider submitting these pathways 
to verification via planned audits, with the aim 
to improve service quality.
Essential items of the informed consent
The BRCA test for prediction of response to 
PARP inhibitors may be prescribed by clini-
cal geneticists, oncologists and gynecologists 
with oncologic expertise. The prescriber has the 
responsibility to provide appropriate information 
to the patients on the genetic aspects associated 
with the results in order to enable them to make 
informed choices. The information provided to 
the patient should cover the potential therapeu-
tic benefits of treatment with a PARP inhibitor, 
together with the possibility of detecting a high 
cancer risk condition for the patient and her rela-
tives. The timing at which informed consent to 
genetic testing is obtained, as well as the modali-
ties, must respect the will of the patient, who 
should be given the possibility to discuss all the 
different implications of genetic testing, such 
as whether or not to tell other family members 
about the test results, before taking the decision.
Physicians who prescribe a BRCA test should 
abide to an appropriate communication and writ-
ten informed consent collection protocol, using 
specific information material and consent forms. 
Oncologists and gynecologists with oncologic exper-
tise who do not have experience in cancer genetics 
must follow a training program which includes ethi-
cal aspects of BRCA testing. Finally, the care path-
way must clearly identify the cancer genetics team 
to be contacted, should the patient require a closer 
examination of the genetic aspects before deciding 
whether or not to undergo the test, as well as for 
those cases which present particular issues.
Conclusion
In conclusion, BRCA mutations represent a 
biomarker predictive of sensitivity to treatment 
with PARP inhibitors, in addition to cancer risk 
assessment. As highlighted in this recommenda-
tion, several issues are associated with diagnostic 
BRCA testing: the screening methods vary across 
laboratories, and yet no standardized tests exist; 
BRCA analyses can reveal changes of unclear 
clinical significance, in addition to variants 
with a pathogenic or neutral role; finally, there 
is a need to devise the most appropriate report 
models, to avoid misinterpretations among cli-
nicians and confusion among the patients. In 
this respect, the combined goal of this recom-
mendation by the Italian scientific societies is 
to improve the outcome of therapy, to promote 
prevention and finally to reduce mortality of 
ovarian cancer.
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